



Menelas N. Pangalos, Ph.D. **Vice President,** **Neuroscience Discovery Research**

Menelas Pangalos is Vice President of Neuroscience Research and co-chair of the Neuroscience Leadership team. He previously served as Group Director and Head of Neurodegenerative Research at GlaxoSmithKline in Harlow, United Kingdom. Dr. Pangalos oversees the neuroscience portfolio focusing on psychiatric and neurological diseases of high unmet medical need. In particular his group is working on developing novel therapies to treat Depression, Anxiety, Schizophrenia, Bipolar Disorder, Alzheimer's disease, Stroke, Parkinson's disease and chronic pain.

Dr Pangalos completed his undergraduate studies with first class honors in Biochemistry from the Imperial College of Science and Technology and earned a PhD in Neurochemistry from the Institute of Neurology, both at the University of London. He has subsequently worked in the Psychiatry Department at Mt. Sinai School of Medicine in New York and with Janssen Pharmaceutica in Belgium.

Dr. Pangalos is an Adjunct Professor of Neuroscience at the University of Pennsylvania and a Visiting Professor at King's College London. He is an executive editor for Neuropharmacology, on the editorial boards of Molecular and Cellular Neuroscience, and The Scientific World and on scientific advisory boards for the Wolfson Centre for Age Related Diseases (King's College London University), Rider University and the National Association for Mental Illness, NJ. He has previously served on the BBSRC Molecular and Cell Biology council and is a member of the American Society for Neuroscience, British Pharmacological Society and an Associate of the Royal College of Science. Dr. Pangalos has edited the book "Understanding G-protein coupled receptors in the CNS", as well as a number of journal issues focused on drug discovery in the CNS. He has published over 100 peer-reviewed articles in journals such as *PNAS*, *Neuron*, *Journal of Neuroscience*, *Nature Neuroscience*, *Nature Drug Discovery*, *The Lancet*, *British Journal of Psychiatry* and *Journal of Biological Chemistry*. In 2008 Dr. Pangalos was recognized as one of six most notable people in R&D by R&D Directions

Email: pangalm@wyeth.com

Selected Publications

1. Robbins MJ, Calver AR, Fillipov AK, Couve A, Moss SJ and Pangalos MN. The GABAB2 subunit is essential for G protein coupling of the GABAB receptor heterodimer. *J. Neuroscience* (2001) 21: 8043-8052.
2. Couve A, Thomas P, Calver A, Hirst WD, Pangalos MN, Walsh FW, Smart T and Moss SJ. A role for cAMP dependent protein kinase phosphorylation in facilitating GABAB receptor effector coupling. *Nature Neuroscience* (2002) 5, 1-10 .
3. Williams G, Williams EJ, Maison P, Pangalos MN, Walsh FW, Doherty P. Overcoming the inhibitors of myelin with a novel neurotrophin strategy. (2005) *J. Biol. Chem.* 280(7): 5862-5869.
4. T.A. Comery, R.L. Martone, S. Aschmies, K.P. Atchison, G. Diamantidis, S. Gong, H. Shou, J. Sonnenberg-Reines, A.F. Kreft, Pangalos MN, J.S. Jacobsen and K.L. Marquis. γ -secretase inhibition improves contextual fear conditioning in a Tg2576 mouse model of AD. *J Neurosci* (2005) 25: 8898 – 8902.
5. Berger Z, Ravikumar B, Menzies FL, Garcia L, Underwood BR, Vacher C, Pangalos MN, Schmitt S, Wullner U, Evert B, O'Kane CJ, Rubinsztein DC. Rapamycin alleviates toxicity of diverse aggregate prone-proteins and pro-apoptotic insults. *Human Molecular Genetics* (2006) 15: 433 - 442.
6. Pangalos MN, Jacobsen SJ and Reinhart PH. Disease Modifying Strategies for the Treatment of Alzheimer's Disease Targeted at Modulating Levels of the β -Amyloid Peptide. *Biochem. Soc. Transactions* (2005) 33 (4), 553-558.
7. Kuramoto N, Wilkins M, Fairfax B, Revilla-Sanchez R, Tamaki K, Couve A, Calver AR, Horvath Z, Freeman K, Carling D, Huang L, Cooper E, Gonlazes C, Cooper E, Smart TG, Pangalos MN, Moss SJ. Phospho-dependent functional modulation of GABA_B receptors by the metabolic sensor AMP-dependent protein kinase. (2006) *Neuron*. 53: 233-247.